Business
2018 Annual Report and 2019 AGM Notice
2018 Annual Report and 2019 AGM Notice.
About this update from Shield Therapeutics Plc
[{"type":"text","content":"\n \nRNS Number : 2290X Shield Therapeutics PLC 30 April 2019 \n\nShield Therapeutics plc\n(\"Shield\" or the \"Company\")\n \n2018 Annual Report and 2019 AGM Notice\n \nLondon, UK, 30 April 2019. Shield Therapeutics plc (LSE:STX), a commercial stage pharmaceutical company with a focus on addressing iron deficiency with or without anaemia via its lead product Feraccru®, announces that the following documents have been sent to shareholders:\n \n· Annual Report and Accounts for the year ended 31 December 2018\n· Notice of Annual General Meeting (\"AGM\") 2019\n \nIn accordance with AIM Rule 26, these documents are available on Company's website at, https://www.shieldtherapeutics.com/investors/corporate-documents/.\n \nThe AGM is scheduled to be held at 10.00am BST on Thursday 13 June 2019 at the offices of Stephenson Harwood LLP, 1 Finsbury Circus, London, EC2M 7SH.\n \nFor further information please contact:\n \n\n\n\nShield Therapeutics plc\n\n\nwww.shieldtherapeutics.com\n\n\n\n\nCarl Sterritt, Chief Executive Officer\n\n\n+44 (0)20 7186 8500\n\n\n\n\nTim Watts, Chief Financial Officer\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nNominated Advisor and Broker\n\n\n\n\n\n\n\nPeel Hunt LLP\n\n\n\n\n\n\n\nJames Steel/Dr Christopher Golden\n\n\n+44 (0)20 7418 8900\n\n\n\n\n\n\n\n\n\n\n\n\nFinancial PR & IR Advisor\n\n\n\n\n\n\n\nWalbrook PR\n\n\n+44 (0)20 7933 8780 or [email protected]\n\n\n\n\nPaul McManus / Helen Cresswell\n\n\n+44 (0)7980 541 893 / +44 (0)7841 917 679\n\n\n\n \nAbout Shield Therapeutics plc\nShield is a de-risked, commercial stage, pharmaceutical company delivering innovative specialty pharmaceuticals to address patients' unmet medical needs. The Company's clear purpose is to help its patients become people again, by enabling them to enjoy the things that make the difference in their everyday lives. The Group has a marketed product, Feraccru®, for the treatment of iron deficiency in adults which has exclusive IP rights until the mid-2030s. Feraccru® is commercialised in the European Union by Norgine BV and the US Food and Drug Administration (FDA) is currently considering a New Drug Application (NDA), with a PDUFA (Prescription Drug User Fee Act) date of 27th July 2019. For more information please ...